echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > J INTERN MED: The relationship between lipoprotein (a) and SARS-CoV-2 infection

    J INTERN MED: The relationship between lipoprotein (a) and SARS-CoV-2 infection

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Complications including ischemic heart disease (IHD) aggravate the condition after SARS-CoV-2 infection
    .


    High lipoprotein (a) [Lp (a) ] levels IHD and thrombotic a strong risk factor for embolic events


    Infected thrombus

    Recently, a research article was published in the Journal of Internal Medicine, an authoritative journal in the field of internal medicine.
    Researchers aim to assess whether SARS-CoV-2 infection changes the risk of high Lp(a) concentrations in predicting IHD or thromboembolic events
    .

    The researchers used the British Biobank to conduct a cohort study on data during the SARS-CoV-2 pandemic, and compared the baseline Lp(a) levels of SARS-CoV-2 positive patients and the population control group
    .


    The British Biobank has obtained ethical approval from the Northwest Multi-Center Research Ethics Committee (REC:11/NW/0382)


    The relationship between Lp(a), SARS-CoV-2, IHD and thromboembolic events

    The Lp(a) concentration of SARS-CoV-2 positive patients was similar to that of the control group
    .


    In population controls (n=435104) and SARS-CoV-2 positive patients (n=6937), as the concentration of Lp(a) increases, the risk of IHD increases


    It can be seen that SARS-CoV-2 infection strengthens the correlation between high Lp(a) levels and IHD, but Lp(a) does not affect the risk of thromboembolic events


    SARS-CoV-2 infection reinforces the correlation between high Lp(a) levels and IHD, but Lp(a) does not affect the risk of thromboembolic events

    Original source:

    Original source:

    Silvia Di Maio.


    Lipoprotein (a) and SARS-CoV -2 infections: susceptibility to infections, ischemic heart disease and thromboembolic events in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.